Anti-SARS-CoV-2 Antibodies Testing in Recipients of COVID-19 Vaccination: Why, When, and How?
Anti-SARS-CoV-2 Antibodies Testing in Recipients of COVID-19 Vaccination: Why, When, and How?
复制标题
DOI：
10.3390/diagnostics11060941
复制
发表时间：
2021-05-25
期刊：
影响因子：
--
通讯作者：
Plebani M
中科院分区：
文献类型：
--
作者：
Lippi G;Henry BM;Plebani M
尽管全民接种疫苗是限制SARS-CoV-2（严重急性呼吸系统综合征冠状病毒2）循环和避免2019冠状病毒病（COVID-19）导致的大量住院和死亡的最重要的医疗保健策略之一，但COVID-19疫苗的效力存在显著的个体间差异，主要是由于接受者的异质性免疫反应。因此，本意见书旨在讨论在COVID-19疫苗接种前后监测抗SARS-CoV-2抗体的机会的相关方面，强调此策略的利弊。总之，在COVID-19疫苗接种者中进行抗SARS-CoV-2抗体检测的优势包括评估未接种疫苗个体中SARS-CoV-2感染的基线血清阳性率;早期识别COVID-19疫苗接种的低应答者或无应答者;以及及时检测抗SARS-CoV-2抗体水平的快速衰减。相比之下，迄今为止的潜在缺点包括：抗SARS-CoV-2抗体滴度、中和活性和疫苗效率之间的等效性未经证实;缺乏对不同检测策略的成本效益分析;需要大量抽血和增加实验室工作量以支持通用抗SARS-CoV-2抗体检测。一种潜在的解决方案需要确定优先进行测试的队列，包括那些被关注的变体感染的风险较高的队列，那些疾病进展不利的风险较高的队列，以及疫苗免疫原性可能较低和/或较短的受试者。
Although universal vaccination is one of the most important healthcare strategies for limiting SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) circulation and averting the huge number of hospitalizations and deaths due to coronavirus disease 2019 (COVID-19), significant inter-individual variability of COVID-19 vaccines’ efficacies has been described, mostly due to heterogeneous immune response in recipients. This opinion paper hence aims to discuss aspects related to the opportunity of monitoring anti-SARS-CoV-2 antibodies before and after COVID-19 vaccination, highlighting the pros and cons of this strategy. In summary, the advantages of anti-SARS-CoV-2 antibodies’ testing in recipients of COVID-19 vaccination encompass an assessment of baseline seroprevalence of SARS-CoV-2 infection in non-vaccinated individuals; early identification of low or non-responders to COVID-19 vaccination; and timely detection of faster decay of anti-SARS-CoV-2 antibody levels. In contrast, potential drawbacks to date include an unproven equivalence between anti-SARS-CoV-2 antibody titer, neutralizing activity, and vaccine efficiency; the lack of cost-effective analyses of different testing strategies; the enormous volume of blood drawings and increase of laboratory workload that would be needed to support universal anti-SARS-CoV-2 antibodies testing. A potential solution entails the identification of cohorts to be prioritized for testing, including those at higher risk of being infected by variants of concern, those at higher risk of unfavorable disease progression, and subjects in whom vaccine immunogenicity may be expectedly lower and/or shorter.
登录
查看更多内容
影响因子：
64.5
作者：
Hoffmann M;Arora P;Groß R;Seidel A;Hörnich BF;Hahn AS;Krüger N;Graichen L;Hofmann-Winkler H;Kempf A;Winkler MS;Schulz S;Jäck HM;Jahrsdörfer B;Schrezenmeier H;Müller M;Kleger A;Münch J;Pöhlmann S
通讯作者：
Pöhlmann S
影响因子：
6.8
作者：
Danese, Elisa;Montagnana, Martina;Lippi, Giuseppe
通讯作者：
Lippi, Giuseppe
影响因子：
6.8
作者：
Bohn, Mary Kathryn;Loh, Tze Ping;Adeli, Khosrow
通讯作者：
Adeli, Khosrow
影响因子：
2.5
作者：
Danese E;Montagnana M;Salvagno GL;Gelati M;Peserico D;Pighi L;de Nitto S;Henry BM;Porru S;Lippi G
通讯作者：
Lippi G
影响因子：
20.3
作者：
Herishanu Y;Avivi I;Aharon A;Shefer G;Levi S;Bronstein Y;Morales M;Ziv T;Shorer Arbel Y;Scarfò L;Joffe E;Perry C;Ghia P
通讯作者：
Ghia P